4010-81-5

Basic information

• Product Name: 2-chloro-6-(morpholin-4-yl)-5H-purine
• CAS NO: 4010-81-5
• Molecular Formula: C₉H₁₀ClN₅O
• Molecular Weight: 239.6616
• Mol File: 4010-81-5.mol

Chemical Properties

• Boiling Point: 373.3°C at 760 mmHg
• Flash Point: 179.6°C
• Density: 1.74g/cm³
• Vapor Pressure: 9.06E-06mmHg at 25°C
• Refractive Index: 1.796
• CAS DataBase Reference: 2-chloro-6-(morpholin-4-yl)-5H-purine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-6-(morpholin-4-yl)-5H-purine(4010-81-5)
• EPA Substance Registry System: 2-chloro-6-(morpholin-4-yl)-5H-purine(4010-81-5)

Safety Data

• Hazardous Substances Data: 4010-81-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-chloro-6-(morpholin-4-yl)-5H-purine is used as a kinase inhibitor for its potential role in the development of targeted therapies against various diseases, including cancer. Its ability to inhibit specific kinases may contribute to the regulation of cellular processes and the suppression of disease progression.
Used in Medicinal Chemistry Research:
As a chemical building block, 2-chloro-6-(morpholin-4-yl)-5H-purine is utilized in the synthesis of other molecules with potential therapeutic applications. Its structural features make it a valuable component in the design and development of novel compounds with improved pharmacological properties.
Used in Drug Discovery:
2-chloro-6-(morpholin-4-yl)-5H-purine serves as a starting point for drug discovery efforts, where its modification and optimization can lead to the creation of new drugs with enhanced efficacy and selectivity. Its potential as a kinase inhibitor highlights its importance in the search for treatments for various diseases.

Upstream product

• 110-91-8 morpholine 
• 5451-40-1 2,6-dichloro-7H-purine 
• 5451-40-1 2,6 dichloropurine 
• 5451-40-1 2,6-dichloropurine 
• 95758-04-6 2-chloro-6-(morpholin-4-yl)-9-(tetrahydro-2H-pyran-2-yl)-9H-purine 
• 149948-30-1 N-(6-chloro-9H-purin-2-yl)formamide 
• 73-40-5 2-amino-1,9-dihydro-6H-purin-6-one 
• 10310-21-1 2-Amino-6-chloropurin 

Downstream Products

• 7474-73-9 6-morpholino-2-piperidino-7(9)H-purine 
• 2846-96-0 6-morpholino-7⁽⁹⁾H-purine 
• 7471-61-6 (6-morpholino-7(9)H-purin-2-yl)-hydrazine 
• 7494-71-5 4,4'-(9H-purine-2,6-diyl)dimorpholine 
• 682337-90-2 [2-(3,4-dimethoxy-phenyl)-ethyl]-(6-morpholin-4-yl-9H-purin-2-yl)amine 
• 1062205-49-5 9-(1-benzyl-piperidin-4-yl)-2-chloro-6-morpholin-4-yl-9H-purine 
• 934545-07-0 3-[6-(4-morpholinyl)-9H-purin-2-yl]-phenol 
• 1148003-91-1 2-chloro-6-morpholin-4-yl-9-[2-(tetrahydropyran-2-yloxy)ethyl]-9H-purine 
• 1062203-86-4 [4-(6-morpholin-4-yl-9H-purin-2-yl)phenyl]methanol 
• 1062203-80-8 2-(6-morpholin-4-yl-9H-purin-2-yl)phenol 
• 1062203-83-1 4-(6-morpholin-4-yl-9H-purin-2-yl)phenol 
• 1062204-03-8 3-(6-morpholin-4-yl-9H-purin-2-yl)benzonitrile 
• 1062204-08-3 N-(3-(6-morpholino-9H-purin-2-yl)phenyl)methanesulfonamide 
• 1062204-17-4 2-[3-(methylsulfonyl)phenyl]-6-morpholin-4-yl-9H-purine 

Relevant articles and documents

High yielding, base catalyzed C6 regioselective amination and N9 alkylation in purine nucleotide

2,6-Dichloropurine is an interesting new nucleoside which gave regioselectively various 2-derivatized or 6-derivatized purines by using a secondary amines. An efficient, simple and regioselective synthesis of C6 morpholine, N9 alkylated purine nucleoside derivatives were attained via chloro-amine coupling reaction between 2,6-dichloropurine with morpholine followed by commercial alkylation method using DMF and K2CO3. Over the traditionally used protocols and procedure, it have been exhibited advance benefits such as admirable yield, simple reaction conditions and modest influence.

Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma

Class I histone deacetylases (HDACs) are highly expressed and/or upregulated in hepatocellular carcinoma (HCC) and are associated with aggressiveness, spread, and increased mortality of HCC. Activation of phosphatidylinositol 3-kinase-Akt-mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway was involved in the development of HCC and acquired resistance to sorafenib. A series of purine or 5H-pyrrolo[3,2-d]pyrimidine based hydroxamates were designed and developed as multitarget drugs to modulate both HDACs and the PI3K/Akt/mTOR pathway. Among 39 cell lines screened, the molecules (e.g., 20e, 20f, and 20q) were the most selective against leukemia, lymphoma, and HCC cells; they also demonstrated target modulation in cancer cell lines and in mice bearing MV4-11 and HepG2 tumors. Compound 20f in particular showed significant single agent oral efficacy in hypervascular liver cancer models (e.g., HepG2, HuH-7, and Hep3B) and was well-tolerated. These encouraging results, along with its favorable target profile and tissue distribution, warrant further development of 20f.

Piperazinone substitute or derivative thereof, preparation method and application thereof, and pharmaceutical composition

The invention relates to a piperazinone substitute or a derivative thereof, a preparation method and application thereof, and a pharmaceutical composition, and belongs to the technical field of anti-tumor drugs. The invention designs a piperazinone substituted heterocyclic small molecule compound. The compound shows good affinity to PI3K delta, and the compound can down-regulate the activity of a PI3K pathway in tumor cells, so that the compound shows good inhibitory activity to PI3K delta dependent tumors, and is expected to be used as one of components of a pharmaceutical preparation for treatment of different tumors. The preparation method of the piperazinone substitute is simple and convenient, and the yield is relatively high.

PURINES AND METHODS OF THEIR USE

Disclosed are compounds useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases.

DUAL KINASE-BROMODOMAIN INHIBITORS

Provided herein are compounds of Formula (I) that are dual inhibitors of kinases and bromo-domain proteins. The disclosure also relates to pharmaceutical compositions containing such compounds, methods for using such compounds in the treatment of cancers, particularly, the treatment of multiple myeloma cancers, and to related uses.

Medicinal Chemistry Optimization of a Diaminopurine Chemotype: Toward a Lead for Trypanosoma brucei Inhibitors

Human African trypanosomiasis (HAT), or sleeping sickness, is caused by the protozoan parasite Trypanosoma brucei and transmitted through the bite of infected tsetse flies. The disease is considered fatal if left untreated. To identify new chemotypes against Trypanosoma brucei, previously we identified 797 potent kinase-targeting inhibitors grouped into 59 clusters plus 53 singleton compounds with at least 100-fold selectivity over HepG2 cells. From this set of hits, a cluster of diaminopurine-derived compounds was identified. Herein, we report our medicinal chemistry investigation involving the exploration of structure-activity and structure-property relationships around one of the high-throughput screening (HTS) hits, N2-(thiophen-3-yl)-N6-(2,2,2-trifluoroethyl)-9H-purine-2,6-diamine (1, NEU-1106). This work led to the identification of a potent lead compound (4aa, NEU-4854) with improved in vitro absorption, distribution, metabolism, and excretion (ADME) properties, which was progressed into proof-of-concept translation of in vitro antiparasitic activity to in vivo efficacy.

Purine compound obtained based on virtual docking as well as preparation method and application of same

The invention provides a purine compound obtained based on virtual docking. The purine compound is screened in a virtual screening and pharmacophore manner, through a result of mutual evidence verification of virtual docking design and compound synthesis,

Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer

In the current study, we have designed and synthesized a series of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent kinase2 (CDK2) dual inhibitors by integrating purine-based pharmacophore into the recognition cap group of CS055. The representative compound 14d with excellent antiproliferative activities towards five solid cancer cells, showed potent inhibitory activities against HDAC1, HDAC2 and CDK2 with IC50 values of 70.7 nM, 23.1 nM and 0.80 μM, respectively. Besides, compound 14d could effectively block the cell cycle in the G2/M phase and induce apoptosis, which might be related to increasing intracellular ROS levels. Importantly, compound 14d exhibited desirable pharmacokinetic (PK) properties with the intraperitoneal bioavailability of 50.8percent in ICR mice, and potent in vivo antitumor activity in the HCT116 xenograft model. Therefore, compound 14d could be considered as a promising lead compound for the development of multitargeting anticancer agents.

Identification of a potent and selective phosphatidylinositol 3-kinase δ inhibitor for the treatment of non-Hodgkin's lymphoma

PI3Kδ has proved to be an effective target for anti-lymphoma drugs. However, the application of current approved PI3Kδ inhibitors has been greatly limited due to their specific immune-mediated toxicity and increased risk of infection, it is necessary to develop more PI3Kδ inhibitors with new scaffold. In this study, SAR study with respect to piperazinone-containing purine derivatives led to the discovery of a potent and selective PI3Kδ inhibitor, 4-(cyclobutanecarbonyl)-1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-2-one (WNY1613). WNY1613 exhibits good antiproliferative activity against a panel of non-Hodgkin's lymphoma (NHL) cell lines by inducing cancer cell apoptosis and inhibiting the phosphorylation of PI3K and MAPK downstream components. In addition, it can also prevent the tumor growth in both SU-DHL-6 and JEKO-1 xenograft models without observable toxicity. WNY1613 thus could be developed as a promising candidate for the treatment of NHL after subsequent extensive pharmacodynamics and pharmacokinetics investigation.

Novel purine derivative compounds, preparation method thereof, pharmaceutical compositions and methods of use (by machine translation)

The invention belongs to the field of pharmaceutical chemicals, relates to mammalian mTOR signal path having effects of inhibiting the formula I compound and its pharmaceutically acceptable salt or hydrate, various substituted group in the general formula I as defined in the specification stated; the formula I compound preparation method: comprising the formula I compound or its pharmaceutically acceptable salt or hydrate of the pharmaceutical composition; the formula I compound or its pharmaceutically acceptable salt or hydrate in use for the production of medicaments, medicament for the treatment of a mammal mTOR path signal moving the diseases caused by the abnormal expression of the. (by machine translation)